



Integra LifeSciences to Present at Upcoming Healthcare Conferences

PLAINSBORO, NJ, Nov. 15, 2006 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it is scheduled to present at the Lazard Capital Markets Life Sciences Conference in New York City on Tuesday, November 28, 2006 and at the Piper Jaffray Healthcare Conference in New York City on Thursday, November 30, 2006.

Both presentations will be delivered by Stuart Essig, President and Chief Executive Officer of Integra. The presentations will not be available via webcast. Copies of the slide presentations are available on the "Presentations and Webcasts" page of the "Investor Relations" section of our website at <http://www.Integra-LS.com>.

Each of the presentations will provide an overview of Integra's operations, with a focus on currently marketed products, sales distribution channels and product pipeline, recent financial history, and Integra's overall business strategy for growth.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. Please visit our website at <http://www.Integra-LS.com>.

Statements made at the upcoming conference may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2005 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation
John B. Henneman, III
Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com
John Bostjancic
Vice President, Corporate Development and Investor Relations
(609) 936-2239
jbostjancic@integra-LS.com